W
WAVEMAN · COMPANY
IDXX · Idexx Laboratories Inc /De
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

IDXX

IDEXX LABORATORIES INC /DE
PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0000874716
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
3
13F, latest reported quarter
REVENUE GROWTH
+10.4%
XBRL, annual
NET MARGIN
24.6%
CONVERSIONS · 180D
9
codes C/M, not in net · $47.2K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
3 funds added or opened last quarter
below 98% of Pharma & Biotech
REVENUE
+10.4% year over year
more than 61% of Pharma & Biotech
MARGIN
24.6% net margin
more than 90% of Pharma & Biotech
BUYBACKS
$697.8M repurchased, FY to 2026-06-30
more than 90% of Pharma & Biotech
SHORT
2.5% of shares outstanding short · 4.0 days to cover · settled 2026-07-31
below 61% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -16.3%
-16.3%12M
-18%-5%+7%+20%2025-092025-102025-122026-032026-052026-072026-09 2025-11-07 · Hunt Nimrata sold $3.6M2026-02-26 · MAZELSKY JONATHAN JAY sold $2.4M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.9M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.9M2026-02-10 · FENNELL GEORGE sold $1.8M2026-02-10 · FENNELL GEORGE sold $1.8M2026-02-26 · Hunt Nimrata sold $1.8M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.7M2026-02-17 · Erickson Michael G sold $1.7M2026-02-10 · FENNELL GEORGE sold $1.4M2026-03-03 · Hunt Nimrata sold $1.1M2026-02-26 · MAZELSKY JONATHAN JAY sold $1.1M2025-11-07 · Hunt Nimrata sold $1.0M2025-11-07 · Hunt Nimrata sold $1.0M2026-02-26 · MAZELSKY JONATHAN JAY sold $975.9K2025-11-07 · Hunt Nimrata sold $972.2K2026-02-26 · MAZELSKY JONATHAN JAY sold $882.1K2026-02-26 · MAZELSKY JONATHAN JAY sold $833.5K2026-02-17 · Erickson Michael G sold $806.6K2026-02-26 · MAZELSKY JONATHAN JAY sold $793.3K2026-02-26 · MAZELSKY JONATHAN JAY sold $765.5K2026-02-26 · MAZELSKY JONATHAN JAY sold $727.3K2026-02-10 · FENNELL GEORGE sold $726.6K2026-02-26 · MAZELSKY JONATHAN JAY sold $713.4K2026-02-10 · FENNELL GEORGE sold $686.0K2026-02-26 · MAZELSKY JONATHAN JAY sold $662.2K2026-02-10 · FENNELL GEORGE sold $626.7K2026-02-17 · Vandebroek Sophie V. sold $594.1K2026-02-17 · Erickson Michael G sold $433.4K2026-02-17 · Vandebroek Sophie V. sold $326.2K2026-02-17 · Erickson Michael G sold $284.4K2026-02-10 · FENNELL GEORGE sold $255.7K2026-02-17 · Erickson Michael G sold $127.5K2026-02-10 · FENNELL GEORGE sold $26.0K2026-02-17 · Erickson Michael G sold $25.2K2026-09-04 · LAWRENCE D KINGSLEY filed to sell $1.2M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows 3 funds added last quarter, $1.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for IDEXX LABORATORIES INC /DE in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Hunt Nimrata
Executive Vice President
SELL
2026-03-03
1,758.0
$1.1M
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-02-26
2,860.0
$1.9M
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-02-26
1,095.0
$713.4K
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-02-26
1,281.0
$833.5K
MAZELSKY JONATHAN JAY
President and CEO
SELL
2026-02-26
2,589.0
$1.7M
220 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 215 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
CAPITAL COUNSEL LLC/NY
419,151.0 sh
$220.7M
DF DENT & CO INC
39,515.0 sh
$20.8M
ACADEMY CAPITAL MANAGEMENT
34,801.0 sh
$18.3M
FRANKLIN STREET ADVISORS INC /NC
26,215.0 sh
$13.8M
Azimuth Capital Investment Management LLC
18,111.0 sh
$9.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
LAWRENCE D KINGSLEY
FILED 2026-09-04
$1.2M
Executive pay vs shareholder return · Jonathan J. Mazelsky
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$14.6M
$31.8M
$3.1M
+35%
+48%
2024
$13.0M
$2.3M
$3.8M
-17%
+29%
2023
$11.5M
$22.7M
$3.3M
+11%
+26%
2022
$9.8M
-$13.8M
$2.8M
-18%
+24%
2021
$9.1M
$28.2M
$2.8M
+32%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$4.3B$3.9B$3.7B$3.4B
GROSS PROFIT$2.7B$2.4B$2.2B$2.0B
OPERATING INCOME$1.4B$1.1B$1.1B$898.8M
NET INCOME$1.1B$887.9M$845.0M$679.1M
EPS (DILUTED)13.0810.6710.068.03
OPERATING CASH FLOW$1.2B$929.0M$906.5M$543.0M
CASH$180.1M$288.3M$453.9M$112.5M
LONG-TERM DEBT$374.8M$449.8M$622.9M$694.4M
BUYBACKS$1.2B$837.0M$71.9M$819.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →